Stockscreener 앱 받기
9.42
8.65%
0.75
시간 외 거래:
9.80
0.38
+4.03%
전일 마감가:
$8.67
열려 있는:
$8.795
하루 거래량:
962.69K
Relative Volume:
1.27
시가총액:
$492.44M
수익:
$88.24M
순이익/손실:
$-160.90M
주가수익비율:
-3.5358
EPS:
-2.6642
순현금흐름:
$-129.35M
1주 성능:
+8.03%
1개월 성능:
+2.95%
6개월 성능:
+2.28%
1년 성능:
+126.99%
1일 변동 폭
$8.725
$9.87
1주일 범위
$8.37
$9.87
52주 변동 폭
$3.68
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.42 | 481.99M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic - Barchart.com
Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema - Nature
FDMT: Gene therapy 4D-150 targets lifelong vision benefit and reduced injections in wet AMD - TradingView
FDMT: 4D-150 gene therapy shows promise for durable wet AMD treatment with strong safety and scalability - TradingView
Insider Sell Alert: David Kirn Sells Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4d molecular therapeutics CEO Kirn sells $19,257 in shares By Investing.com - Investing.com Australia
4d molecular therapeutics CEO Kirn sells $19,257 in shares - Investing.com
Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
Number of shareholders of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Opus Genetics Slides Ahead of June Test - Bez Kabli
IonQ Aktie: Two Sigma kauft 2,17 Millionen Aktien - Finanztrends
4D Molecular Therapeutics (FDMT) Gains 1.6% as Stock Holds Above SupportThematic ETF Flow - The Legal Advocate
4DMT to Participate in Upcoming Investor Conferences - The Globe and Mail
Pittsburgh Post-Gazette - FinancialContent
4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - Insider Monkey
4D Molecular Therapeutics, Inc.Common Stock (NQ: FDMT - FinancialContent
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
FDMT: Pivotal global trials advance a disruptive, lifelong gene therapy for retinal disease - TradingView
About Us - FinancialContent
User | mammothtimes.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
User | malvern-online.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares - Stock Titan
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants - Stock Titan
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees - Stock Titan
Fat Pitch Financials4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
[EFFECT] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - MSN
FDMT: 4D-150's phase III progress and robust data position it as a potential game-changer in retinal gene therapy - TradingView
State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026 - Stock Titan
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report - simplywall.st
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged - TipRanks
4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
4D Molecular Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.62, Implies 178% Upside - TradingView
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) files $400M shelf registration - Stock Titan
Wet AMD gene therapy moves ahead; 4DMT targets 2027 Phase 3 data - Stock Titan
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
4D Molecular (NASDAQ: FDMT) details Q1 loss and cash runway to 2028 - Stock Titan
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):